Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
The Proteasome01:13

The Proteasome

953
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
953
Regulated Protein Degradation02:58

Regulated Protein Degradation

7.5K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
The Proteasome Structure01:17

The Proteasome Structure

841
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
841

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rescue of the First Mitochondrial Membrane Carrier, the mPiC, by TAT-Mediated Protein Replacement Treatment.

International journal of molecular sciences·2025
Same author

Inducing Targeted, Caspase-Independent Apoptosis with New Chimeric Proteins for Treatment of Solid Cancers.

Cancers·2025
Same author

Cathepsin B promotes Aβ proteotoxicity by modulating aging regulating mechanisms.

Nature communications·2024
Same author

Author Correction: ASS1 metabolically contributes to the nuclear and cytosolic p53-mediated DNA damage response.

Nature metabolism·2024
Same author

ASS1 metabolically contributes to the nuclear and cytosolic p53-mediated DNA damage response.

Nature metabolism·2024
Same author

The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness.

Proceedings of the National Academy of Sciences of the United States of America·2024

Related Experiment Video

Updated: Aug 15, 2025

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.6K

Exploiting the Endogenous Ubiquitin Proteasome System in Targeted Cancer Treatment.

Noa Hauser1, Joud Hirbawi1, Meshi Saban Golub1

  • 1Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.

Cancers
|January 8, 2023
PubMed
Summary

We created a novel chimeric protein, IL2-Smurf2, for targeted cancer therapy. This dual-function protein specifically targets cancer cells, inducing apoptosis and showing potential in leukemia models.

Keywords:
HECT E3 ligaseIL-2IL-2RSmurf2chimeric proteinstargeted therapy

More Related Videos

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
10:26

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations

Published on: November 7, 2019

5.6K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.9K

Related Experiment Videos

Last Updated: Aug 15, 2025

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.6K
Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
10:26

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations

Published on: November 7, 2019

5.6K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer therapeutics often lack specificity, leading to side effects.
  • Targeted therapies aim to improve efficacy and reduce toxicity.
  • Chimeric proteins offer a strategy for dual targeting and effector functions.

Purpose of the Study:

  • To develop and characterize a novel chimeric protein, IL2-Smurf2, for targeted cancer treatment.
  • To assess the specificity, biological activity, and in vivo efficacy of IL2-Smurf2.
  • To establish the feasibility of using Smurf2 as a killing component in chimeric proteins.

Main Methods:

  • Production and variant generation of the IL2-Smurf2 chimeric protein.
  • Western blot analysis to confirm specific cellular entry.
  • Assessment of apoptotic cell death and E3 ligase activity (ubiquitination).
  • In vivo testing in a mouse model of leukemia.

Main Results:

  • IL2-Smurf2 specifically entered target cells.
  • The protein induced apoptotic cell death, unlike inactive variants.
  • IL2-Smurf2 demonstrated E3 ligase activity, promoting protein degradation.
  • In vivo studies showed potential for targeted cancer cell treatment.

Conclusions:

  • IL2-Smurf2 is a novel chimeric protein with dual functionality for targeted cancer therapy.
  • Smurf2 is feasible as a killing component in chimeric targeting proteins.
  • This approach offers a potent and specific strategy for cancer treatment.